BioMarin Pharmaceutical Inc (NASDAQ: BMRN), a US-based global biotechnology company, announced on Friday that it has received accelerated approval from the United States Food and Drug Administration (FDA) for its VOXZOGO (vosoritide) for Injection intended to raise linear growth in paediatric patients with achondroplasia five years of age and older with open epiphyses (growth plates).
The indication has been approved under accelerated approval based on an improvement in annualised growth velocity. Continued approval for this indication is likely to be contingent upon verification and description of clinical benefit in confirmatory studies. In order to complete this post-marketing requirement, the company aims to use the ongoing open-label extension studies compared to available natural history.
The product is the first US FDA approved treatment for children with achondroplasia. It is likely to be offered in the United States by mid- to late-December, and BioMarin is to commence promotion of the product immediately. The approval for the product was based on the results of a global randomised, double-blind, placebo-controlled Phase three study assessing the efficiency and safety of the product and the open-label extension of this Phase three study.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial